Temab-A an ADC antiMET good activty in MET+ nonSq pretreted wt and EGFRm NSCLC. But: easy to test biomarker in daily practice? In EGFRm cohort higher activity if we add osimertinib

Jordi Remon· @JordiRemon · X·2026-10-24 15:49· 22 小时前评分45

正文 · 原文

Temab-A an ADC antiMET good activty in MET+ nonSq pretreted wt and EGFRm NSCLC. But: easy to test biomarker in daily practice? In EGFRm cohort higher activity if we add osimertinib? Is really MET+ a predictive biomarker for Temab-A activity in EGFRm? Brain activity? #ESMO2026

26 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2719RO按 Rapid oral 1: NSCLC, metastatic 对上

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)

https://esmocongress.esmo.org

LBA73按 Rapid oral 1: NSCLC, metastatic 对上

PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line

https://esmocongress.esmo.org

来源：Jordi Remon · x.com